C'mere and gimme some sugar! Sanofi's much-anticipated bid for Genzyme should arrive some time this weekend, or maybe Monday. Repor...

By Joseph Haas Reading the sometimes conflicting data from the venture capital sector can be just a bit confusing. Last time out, for exampl...

FDA just wrapped up a two day public meeting to review the implementation of its Risk Evaluation & Mitigation Strategy authorities. The ...

On Friday, it seemed like everything happened at once. Generic Lovenox . Teva saying generic Lovenox doesn't mean generic Copaxone (we...

On Tuesday, Medigene said it had landed €25 million from its Eligard partner Astellas as part of a renegotiation of the companies' dist...

Roche's CEO Severin Schwan isn't the only pharma CEO facing a highly unappealing economic reality (and not just talking of it) – exe...

We're not ones to call advisory committee members names. We'll let them do that to themselves. "I was one of the brain-dead kan...

We hope you enjoyed a lazy summer weekend, and a welcome respite from last week's non-stop craziness. Meanwhile if you're looking fo...

Befitting the above image from Inception of the streets of Paris getting wrapped up like the subject of a misinterpreted Manfred Mann tune,...

It's not quite thirteen ways of looking at a blackbird , but the two main venture surveys have delivered two different ways of looking a...